DE60023903D1 - Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren - Google Patents

Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren

Info

Publication number
DE60023903D1
DE60023903D1 DE60023903T DE60023903T DE60023903D1 DE 60023903 D1 DE60023903 D1 DE 60023903D1 DE 60023903 T DE60023903 T DE 60023903T DE 60023903 T DE60023903 T DE 60023903T DE 60023903 D1 DE60023903 D1 DE 60023903D1
Authority
DE
Germany
Prior art keywords
triones
pyrimidin
metaloproteinase inhibitors
metaloproteinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023903T
Other languages
English (en)
Inventor
Julian Blagg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60023903D1 publication Critical patent/DE60023903D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60023903T 1999-08-12 2000-08-03 Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren Expired - Lifetime DE60023903D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14854799P 1999-08-12 1999-08-12
PCT/IB2000/001090 WO2001012611A1 (en) 1999-08-12 2000-08-03 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
DE60023903D1 true DE60023903D1 (de) 2005-12-15

Family

ID=22526231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023903T Expired - Lifetime DE60023903D1 (de) 1999-08-12 2000-08-03 Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren

Country Status (41)

Country Link
US (1) US6579982B1 (de)
EP (1) EP1202974B1 (de)
JP (1) JP2003507371A (de)
KR (2) KR20020047119A (de)
CN (1) CN1156454C (de)
AR (1) AR025091A1 (de)
AT (1) ATE309224T1 (de)
AU (1) AU773751B2 (de)
BG (1) BG106406A (de)
BR (1) BR0013081A (de)
CA (1) CA2381551A1 (de)
CO (1) CO5180629A1 (de)
CR (1) CR6565A (de)
CZ (1) CZ2002355A3 (de)
DE (1) DE60023903D1 (de)
EA (1) EA004680B1 (de)
EC (1) ECSP003610A (de)
EE (1) EE200200069A (de)
GE (1) GEP20053424B (de)
GT (1) GT200000137A (de)
HK (1) HK1045995B (de)
HN (1) HN2000000137A (de)
HR (1) HRP20020129A2 (de)
HU (1) HUP0202501A3 (de)
IL (1) IL148035A0 (de)
IS (1) IS6248A (de)
MA (1) MA26812A1 (de)
MX (1) MXPA02001561A (de)
NO (1) NO20020662L (de)
NZ (1) NZ516562A (de)
OA (1) OA12000A (de)
PA (1) PA8498701A1 (de)
PE (1) PE20010491A1 (de)
PL (1) PL353871A1 (de)
SK (1) SK1652002A3 (de)
TN (1) TNSN00169A1 (de)
TR (1) TR200200381T2 (de)
UY (1) UY26285A1 (de)
WO (1) WO2001012611A1 (de)
YU (1) YU6602A (de)
ZA (1) ZA200201070B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA03003734A (es) * 2000-10-26 2003-07-28 Pfizer Prod Inc Inhibifores de metaloproteinasa del tipo pirimidin-2, 4, 6-triona.
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AP2001002318A0 (en) * 2000-10-26 2001-12-31 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
JP2004518726A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ベンゾチアジアジンマトリックスメタロプロテイナーゼ阻害剤
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DE60236851D1 (en) 2001-02-14 2010-08-12 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
JP2005529889A (ja) * 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
MXPA04008563A (es) * 2002-04-26 2004-12-06 Pfizer Prod Inc Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
MXPA04010545A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida.
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
BR0313384A (pt) 2002-08-13 2005-07-12 Warner Lambert Co Derivados de cromona como inibidores de metaloproteinases de matriz
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
EP1613269B1 (de) 2003-04-04 2015-02-25 Incyte Corporation Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US20150366275A1 (en) * 2014-06-19 2015-12-24 Gyula Cserfoi Wearable Signaling Device
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263932A1 (en) * 1996-08-28 1998-03-05 Yetunde Olabisi Taiwo 1,4-heterocyclic metalloprotease inhibitors
ES2247707T3 (es) * 1997-06-21 2006-03-01 Roche Diagnostics Gmbh Derivados del acido barbiturico con actividad antimetastasica y antitumoral.

Also Published As

Publication number Publication date
JP2003507371A (ja) 2003-02-25
MA26812A1 (fr) 2004-12-20
HN2000000137A (es) 2001-02-02
SK1652002A3 (en) 2002-09-10
EP1202974A1 (de) 2002-05-08
HUP0202501A3 (en) 2003-02-28
YU6602A (sh) 2004-11-25
BG106406A (en) 2002-09-30
IL148035A0 (en) 2002-09-12
TR200200381T2 (tr) 2002-05-21
HRP20020129A2 (en) 2004-04-30
UY26285A1 (es) 2001-03-16
CN1156454C (zh) 2004-07-07
EP1202974B1 (de) 2005-11-09
ATE309224T1 (de) 2005-11-15
MXPA02001561A (es) 2002-07-02
NO20020662D0 (no) 2002-02-11
AU773751B2 (en) 2004-06-03
PE20010491A1 (es) 2001-04-25
ZA200201070B (en) 2003-04-30
NZ516562A (en) 2003-06-30
WO2001012611A1 (en) 2001-02-22
HK1045995A1 (en) 2002-12-20
KR20040073608A (ko) 2004-08-19
GT200000137A (es) 2002-02-01
KR20020047119A (ko) 2002-06-21
CO5180629A1 (es) 2002-07-30
BR0013081A (pt) 2002-04-23
PA8498701A1 (es) 2002-08-26
GEP20053424B (en) 2005-01-25
HUP0202501A2 (hu) 2002-12-28
EA200200058A1 (ru) 2002-06-27
TNSN00169A1 (fr) 2005-11-10
US6579982B1 (en) 2003-06-17
CR6565A (es) 2004-02-23
CN1368963A (zh) 2002-09-11
HK1045995B (zh) 2004-12-31
AR025091A1 (es) 2002-11-06
NO20020662L (no) 2002-04-09
CZ2002355A3 (cs) 2002-07-17
EA004680B1 (ru) 2004-06-24
ECSP003610A (es) 2002-03-25
OA12000A (en) 2006-04-18
EE200200069A (et) 2003-04-15
CA2381551A1 (en) 2001-02-22
AU6010500A (en) 2001-03-13
PL353871A1 (en) 2003-12-01
IS6248A (is) 2002-01-25

Similar Documents

Publication Publication Date Title
DE60023903D1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE60034683D1 (de) 3(5)-ureido-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE59803292D1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3-liganden
ATE375983T1 (de) Bakterielle gyrase-hemmer und deren verwendung
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
ATE271066T1 (de) Lösliche mutante ctla4 moleküle und deren verwendung
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE330955T1 (de) Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.
DE60045321D1 (de) Mutilinderivate und deren Verwendung als antimikrobielle Agenzien
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
EE200300195A (et) Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
DE60034713D1 (de) Chinolyl-propyl-piperidinderivate und deren Verwendung als antimikrobielle Wirkstoffe
ATE273283T1 (de) Diphenylharnstoffderivate und deren verwendung als alpha2/5-ht2c antagonisten
DE50115716D1 (de) Tetrakisfluoroalkylborat-Salze und deren Verwendung als Leitsalze
ATE293620T1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
ATE300525T1 (de) Uracilverbindungen und deren verwendung
ATE283844T1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
ATE340784T1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
DE50011452D1 (de) Polyalkenalkohol-polyalkoxylate und deren verwendung in kraft- und schmierstoffen
DE50008549D1 (de) Triazolotriazinone und ihre verwendung

Legal Events

Date Code Title Description
8332 No legal effect for de